Cosciens Biopharma Inc (CSCI)

$3.00 +0.11 (3.81%)
Market Cap 11.28M
Revenue (ttm) 4.50M
Net Income (ttm) -16.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -367.78%
Debt to Equity Ratio 0.00
Volume 5,400
Avg Vol 7,724
Day's Range N/A - N/A
Shares Out 3.76M
Stochastic %K 26%
Beta 1.52
Analysts Strong Buy
Price Target N/A

Latest News on CSCI

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

Dec 23, 2024, 7:45 AM EST - 27 days ago

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Nov 12, 2024, 7:30 AM EST - 2 months ago

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

COSCIENS Biopharma Announces Change to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 3 months ago

COSCIENS Biopharma Announces Change to Board of Directors

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

Oct 1, 2024, 5:30 PM EDT - 3 months ago

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

Sep 23, 2024, 7:30 AM EDT - 4 months ago

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aug 27, 2024, 7:30 AM EDT - 5 months ago

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 8:05 AM EDT - 5 months ago

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results